摘要
目的观察信迪利单抗联合含铂双药化疗一线治疗晚期非小细胞肺癌的疗效及安全性。方法43例晚期非小细胞肺癌患者,一线采用信迪利单抗联合含铂双药方案治疗。结果23例(53.4%)部分缓解,16例(37.21%)疾病稳定,4例(9.30%)出现疾病进展。中位无进展生存期为10.3个月,中位总生存时间未达到。有40例患者(93.02%)发生了不同等级的不良事件。结论信迪利单抗联合含铂双药方案一线治疗晚期肺癌能获得较好的疗效,不良反应的早期识别并早期治疗至关重要。
Objective Observe the clinical efficacy and safety of Sintilimabplusplatinumbased chemotherapyas first-Line treatment formetastatic NSCLC.Methods Clinical outcomes of 43 patients with metastatic NSCLC were analyzed.These patients received SintilimabPlus platinumbased chemotherapy as First-LineTreatment.Results 23 cases(53.4%)got partial response(PR),16 cases(37.21%)had stable disease(SD)and 4 cases(9.30%)had progressivedisease(PD).The median progressionfree survival(PFS)was 10.3 months,and the overall survival was not reached.40(93.02%)patients experienced adverse events of different grades.Conclusion The combination of Sintilimabplus platinumbased chemotherapy as first-linetreatment for metastatic NSCLC was found to beeffective.Early identification and correct judgment of adverse eventswere very important.
作者
詹丽芬
杨琼玲
李莹莹
ZHAN Lifen;YANG Qiongling;LI Yingying(Zhangzhou Affiliated Hospital of Fujian Medical University,Zhangzhou 363000,China)
出处
《中国医药指南》
2021年第31期64-66,69,共4页
Guide of China Medicine
